MYC and mature T-cell and NK-cell non-Hodgkin lymphoma: This synergistic interaction appears to be mediated, at least partially, through the downregulation of the MYC signaling pathway, thereby underscoring the potential clinical relevance of this combination therapy in improving treatment outcomes for patients with R/R PTCL.